Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis

Journal of Urology

Volumn 158, Issue 6, 1997, Pages 2069-2073

  Ettinger, Bruce ^a   Pak, Charles Y C ^b   Citron, John T ^b   Thomas, Carl ^b   Adams Huet, Beverley ^b   Vangessel, Arline ^b  

^a DIVISION OF RESEARCH   (United States)

^b NONE

Author keywords

Calcium oxalate; Citrates; Kidney calculi; Magnesium; Potassium

Indexed keywords

CITRIC ACID; PLACEBO; POTASSIUM MAGNESIUM CITRATE; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CALCIUM OXALATE STONE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NEPHROLITHIASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT FAILURE;

EID: 0030829721     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)68155-2     Document Type: Article

References (14)

1. Pak, C. Y. C., Fuller, C., Sakhaee, K., Preminger, G. M., Britton, F. Long-term treatment of calcium nephrolithiasis with potassium citrate. J. Urol., 134: 11, 1985.
2. Pak, C. Y. C. Citrate and renal calculi. Miner Electrolyte Metab., 13: 257, 1987.
3. Kok, D. J., Papapoulos, S. E., Bijvoet, O. L. M. Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet, 1: 1056, 1986.
4. 3 in skin fibroblasts from patients with absorptive hypercalciuria. Calcif. Tissue Int., in press.
5. Preminger, G. M., Baker, S., Peterson, R., Poindexter, J. and Pak, C. Y. C. Hypomagnesiuric hypocitraturia: an apparent new entity for calcium nephrolithiasis. J. Lithotripsy Stone Dis., 1: 22, 1989.
6. Moore, C. A. and Bunce, G. E. Reduction in frequency of renal calculus formation by oral magnesium administration: a preliminary report. Invest. Urol., 2: 7, 1964.
7. Meyer, J. L. and Smith, L. H. Growth of calcium oxalate crystals. I. A model for urinary stone growth. Invest. Urol., 13: 31, 1975.
8. Johansson, G., Backman, U., Danielson, B. G., Fellström, B., Ljunghall, S. and Wikström, B. Magnesium metabolism in renal stone formers. Effects of therapy with magnesium hydroxide. Scand. J. Urol. Nephrol., 53: 125, 1980.
9. Wilson, D. R., Strauss, A. L. and Manuel, M. A. Comparison of medical treatments for the prevention of recurrent calcium nephrolithiasis [abstract]. Urol. Res., 12: 39, 1984.
10. Ettinger, B., Citron, J. T., Livermore, B. and Dolman, L. I. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J. Urol., 139: 679, 1988.
11. 28 in man. Metabolism 9: 646, 1960.
12. Koenig, K., Padalino, P., Alexandrides, G. and Pak, C. Y. C. Bioavailability of potassium and magnesium, and citraturic response from potassium-magnesium citrate. J. Urol., 145: 330, 1991.
13. Pak, C. Y. C., Koenig, K., Khan, R., Haynes, S. and Padalino, P. Physicochemical action of potassium-magnesium citrate in nephrolithiasis. J. Bone Miner Res., 7: 281, 1992.
14. Pak, C. Y. C., Skurla, C. and Harvey, J. Graphic display of urinary risk factors for renal stone formation. J. Urol., 134: 867, 1985.